EdgeRock Capital’s Moderna MRNA Stock Holding History

EdgeRock Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-202	Closed	-$24K	–	209
2024 Q2	$24K	Buy	+202	New	+$25.6K	0.02%	164
2024 Q1	–	Sell	-194	Closed	-$18.9K	–	228
2023 Q4	$18.9K	Buy	+194	New	+$16.3K	0.01%	187

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EdgeRock Capital's MRNA Position: Q3 2024 in Review

EdgeRock Capital sold out of Moderna (MRNA) in Q3 2024, closing a stake of 202 shares — an estimated $24K sold.

EdgeRock Capital first reported a position in MRNA in Q4 2023 and held it in 2 quarters. The position peaked at $24K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

EdgeRock Capital reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
EdgeRock Capital sold 202 Moderna shares in Q3 2024, an estimated $24K.
EdgeRock Capital first reported a position in Moderna in Q4 2023 and held it in 2 quarters.
EdgeRock Capital's Moderna position peaked at $24K in Q2 2024.
788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on EdgeRock Capital's 13F filing for Q3 2024, filed 15 Oct 2024.